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ABSTRACT
It is now appreciated that long non-coding RNAs (lncRNAs) are important players in
orchestrating cancer progression. In this study we characterized GHSROS, a human
lncRNA gene on the opposite DNA strand (antisense) to the ghrelin receptor gene,
in prostate cancer. The lncRNA was upregulated by prostate tumors from different
clinical datasets. Transcriptome data revealed that GHSROS alters the expression of
cancer-associated genes. Functional analyses in vitro showed that GHSROS mediates
tumor growth, migration and survival, and resistance to the cytotoxic drug docetaxel.
Increased cellular proliferation of GHSROS-overexpressing PC3, DU145, and LNCaP
prostate cancer cell lines in vitro was recapitulated in a subcutaneous xenograft model.
Conversely, in vitro antisense oligonucleotide inhibition of the lncRNA reciprocally
regulated cell growth andmigration, and gene expression.Notably,GHSROSmodulates
the expression of PPP2R2C, the loss of which may drive androgen receptor pathway-
independent prostate tumor progression in a subset of prostate cancers. Collectively,
our findings suggest that GHSROS can reprogram prostate cancer cells toward a more
aggressive phenotype and that this lncRNAmay represent a potential therapeutic target.
Subjects Cell Biology, Molecular Biology
Keywords Long non-coding RNA, lncRNA, Prostate cancer, Antisense transcript, Tumour
growth, Gene expression
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INTRODUCTION
The human genome yields a multitude of RNA transcripts with no obvious protein-coding
ability, collectively termed non-coding RNAs (ncRNAs) (Mattick & Rinn, 2015). This
concept is currently being challenged however, as some ncRNA give rise to small peptides
and proteins (Ruiz-Orera et al., 2014; Choi, Kim & Nam 2019;Wang et al., 2019). A decade
of intensive research has revealed that many ncRNAs greater than 200 nucleotides in length
have expression patterns and functions as diverse as protein-coding RNAs (Mattick & Rinn,
2015; Huarte, 2015). These long non-coding RNAs (lncRNAs) have emerged as important
regulators of gene expression, acting on nearby (cis) or distant (trans) protein-coding genes
(Huarte, 2015). Although the vast majority of lncRNAs remain uncharacterized, it is clear
that they play key regulatory roles in development, normal physiology, and disease.
We previously identified GHSROS (also known as AS-GHSR), a 1.1-kb capped and
polyadenylated lncRNA gene antisense to the intronic region of the ghrelin receptor gene
(GHSR) (Whiteside et al., 2013) (Fig. 1A). GHSROS harbors a putative human-specific
promoter in a transposable element (Whiteside et al., 2013), a pattern frequently found in
promoters of lncRNAswhich have high tissue specificity and low expression levels (Saxonov,
Berg & Brutlag, 2006; Derrien et al., 2012). It is now appreciated that many lncRNAs are
equivalent to classical oncogenes or tumor suppressors and drive similar transcriptional
programs in diverse cancer types (Huarte, 2015). Indeed, our earlier study showed that
GHSROS is overexpressed in lung and breast cancer and that its forced overexpression
increases migration in derived cancer lines (Whiteside et al., 2013; Thomas et al., 2019). We
speculated thatGHSROS plays a role in other cancers. Prostate cancer is a disease diagnosed
in nearly 1.5millionmenworldwide annually (Fitzmaurice et al., 2015). Recent studies have
revealed that, like breast cancer, prostate cancer is a heterogeneous disease with multiple
molecular phenotypes (Tosoian & Antonarakis, 2017; Shoag & Barbieri, 2016; Dagogo-Jack
& Shaw, 2018). The identification of genes that drive or mediate these distinct phenotypes
is crucial. Although a number of lncRNAs have been reported in prostate cancer, few
have been functionally characterized or assessed as therapeutic targets (Mouraviev et al.,
2016). Here, we report that GHSROS is highly expressed in a subset of prostate tumors.
We provide evidence that this lncRNA reprograms prostate cancer cells toward a more
aggressive phenotype, possibly by repressing the expression of the tumor suppressor
PPP2R2C to allow androgen-independent growth.
MATERIALS AND METHODS
Assessment of GHSROS transcription in public high-throughput
datasets
To expand on Northern blot and qRT-PCR analyses, which suggest that the lncRNA
GHSROS is expressed at low levels (Whiteside et al., 2013), we interrogated ∼4,000
oligonucleotide microarrays with probes for known and predicted exons (Affymetrix
GeneChip Exon 1.0 ST). An RNA-sequencing dataset averaging ∼160M reads from
metastatic castration-resistant prostate cancer was also examined. See Supplementary
information and Table S10.
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Figure 1 Overview of the lncRNAGHSROS and its expression in cancer. (A) The GHSR and GHSROS
gene loci. GHSR exons (black), GHSROS exon (red), repetitive elements (orange), introns (lines). (B) GH-
SROS expression in 19 cancers (TissueScan Cancer Survey Tissue qPCR panel). N (black) denotes nor-
mal tissue; T tumor (red). For each cancer, data are expressed as mean fold change using the compara-
tive 2−11Ct method against a non-malignant control tissue. Normalized to β-actin (ACTB). (C) Relative
gene expression of GHSROS in OriGene cDNA panels of tissues from normal prostate (n= 24; blue), pri-
mary prostate cancer (n= 88; red), and other prostatic diseases (n= 31; orange). Determined by qRT-
PCR, normalized to ribosomal protein L32 (RPL32), and represented as standardized expression values
(Z -scores). (D) GHSROS expression in an Andalusian Biobank prostate tissue cohort. Absolute expres-
sion levels were determined by qRT-PCR and adjusted by a normalization factor calculated from the ex-
pression levels of three housekeeping genes (HPRT, ACTB, and GAPDH ). NP denotes non-malignant
prostate. *P ≤ 0.05, Mann–Whitney-Wilcoxon test. (E) Expression of GHSROS in immortalized, cul-
tured cell lines and patient-derived xenograft (PDX) lines. Mean± s.e.m. (n= 3). *P ≤ 0.05, **P ≤ 0.01,
*** P ≤ 0.001, Student’s t -test. Normalized as in (b) to the RWPE-1 non-malignant cell line. Androgen-
independent lines are labeled in orange.
Full-size DOI: 10.7717/peerj.10280/fig-1
Cell culture, prostate cancer patient derived xenograft (PDX) models,
and treatments
The PC3 (ATCC CRL-1435), DU145 (ATCC HTB-81), LNCaP (ATCC CRL-1740), and
22Rv1 (ATCCCRL-2505) prostate cancer cell lines, the ES-2 ovarian cancer cell line (ATCC
CRL-1978), and the A549 lung cancer cell line (ATCC CCL-185), were obtained from the
American Type Culture Collection (ATCC, Rockville, MD, USA) and the DuCaP (Lee et
al., 2001) cell line from. The C4-2B (Thalmann et al., 1994) prostate cancer cell line, six
LuCaP prostate-derived xenograft (PDX) lines (Nguyen et al., 2017), and the BM18 PDX
cell line (McCulloch et al., 2005) were available in our laboratory. All prostate cancer and
the ovarian cancer cell line were maintained in Roswell Park Memorial Institute (RPMI)
1640 medium (RPMI-1640; Invitrogen, Carlsbad, CA) with 10% Fetal Calf Serum (FCS,
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Thermo Fisher Scientific Australia, Scoresby, VIC, Australia), supplementedwith 100U/mL
penicillin G and 100 ng/mL streptomycin (Invitrogen). The A549 cell line was maintained
in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) medium
(Invitrogen) with 10% FCS (Thermo Fisher Scientific Australia) supplemented with 100
U/mL penicillin G and 100 ng/mL streptomycin (Invitrogen). The non-tumorigenic
RWPE-1 (ATCC CRL-11609) and the transformed, tumorigenic RWPE-2 (ATCC CRL-
11610) prostate epithelium-derived cell lines were cultured in keratinocyte serum-free
medium (Invitrogen) supplemented with 50 µg/mL bovine pituitary extract and five
ng/mL epidermal growth factor (Invitrogen). All cell lines were passaged at 2- to 3-day
intervals on reaching 70% confluency using TrypLE Select (Invitrogen). Cell morphology
and viability were monitored by microscopic observation and regular Mycoplasma testing
was performed (Universal Mycoplasma Detection Kit, ATCC). Cells were treated with 10
µM enzalutamide (ENZ; Selleck Chemicals, Houston, TX, USA) or 1–20 nM docetaxel
(DTX; Sigma Aldrich, St. Louis, MO, USA) for 96 h (functional assays) or 48 h (qRT-PCR)
and compared to dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis, MO, USA) vehicle
control.
GHSROS qRT-PCR interrogation of human tissue specimens
To investigate the expression of GHSROS in cancer, we initially interrogated a TissueScan
Cancer Survey Tissue qPCR panel (CSRT102; OriGene, Rockville, MD, USA); cDNA
arrayed on multi-well PCR plates. Expression was compared between tumour and normal
tissue. For each cancer type, data were expressed as mean fold change using the comparative
2−11Ct method against a non-malignant control tissue and normalized to β-actin (ACTB).
To further investigate the expression of GHSROS in prostate cancer TissueScan Prostate
Cancer Tissue qPCR panels (HPRT101, HPRT102, and HPRT103) were obtained from
OriGene. The cDNA panels contained of a total of 24 normal prostate-derived samples,
31 abnormal prostate samples (defined as lesions), and 88 prostate tumor samples. These
panels were examined by qRT-PCR, as described above, except that the housekeeping gene
ribosomal protein L32 (RPL32) was employed.
An independent cohort was obtained from the Andalusian Biobank (Servicio Andaluz
de Salud, Spain). It consisted of tissue from 28 patients with clinical high-grade prostate
cancer (10 localized and 18 metastatic tumors) and 8 normal prostate tissue samples.
RT-PCR was performed using Brilliant III SYBR Green Master Mix and a Stratagene
Mx3000p instrument (both from Agilent, La Jolla, CA, USA), as previously described
(Hormaechea-Agulla et al., 2016). Briefly, samples on the same plate were analysed with
a standard curve to estimate mRNA copy number (tenfold dilutions of synthetic cDNA
template for each transcript). No-RNA controls were carried out for all primer pairs.
To control for variations in the amount of RNA used, and the efficiency of the reverse-
transcription reaction, the expression level (copy number) of each transcript was adjusted
by a normalization factor (NF) obtained from the expression of three housekeeping genes
(ACTB, HPRT, and GAPDH ) using the geNorm algorithm (Vandesompele et al., 2002).
Primers used are listed in Table S11.
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Production of GHSROS overexpressing cancer cell lines
Full-length GHSROS transcript was cloned into the pTargeT mammalian expression
vector (Promega, Madison, WI). PC3, DU145, and A549 cell lines were transfected with
GHSROS-pTargeT DNA, or vector alone (empty vector), (using Lipofectamine LTX,
Invitrogen) according to the manufacturer’s instructions. Cells were incubated for 24 h
in LTX and selected with geneticin (100–1,500 µg/mL G418, Invitrogen). As LNCaP
prostate cancer cells were difficult to transfect using lipid-mediated transfection, we
employed lentiviral transduction. Briefly, pReceiver-Lv105 vectors, expressing full length
GHSROS, or empty control vectors, were obtained from GeneCopoeia (Rockville, MD).
For stable overexpression, LNCaP cells were seeded at 50–60% confluency and transduced
with GHSROS, or empty vector control lentiviral constructs in the presence of 8 µg/ml
polybrene (Sigma Aldrich). Following a 48-hour incubation period, transduced cells
were selected with 1 µg/mL puromycin (Invitrogen). GHSROS expression was confirmed
approximately 3 weeks after selection by qRT-PCR, every 2–3 weeks, and before every
functional experiment (see Fig. S5).
RNA extraction, reverse transcription and quantitative reverse
transcription Polymerase Chain Reaction (qRT-PCR)
Total RNA was extracted from cell pellets using an RNeasy Plus Mini Kit (QIAGEN,
Hilden, Germany) with a genomic DNA (gDNA) Eliminator spin column. To remove
contaminating genomic DNA, 1 µg RNA was DNase treated prior to cDNA synthesis with
Superscript III (Invitrogen). qRT-PCR was performed using the AB7500 FAST sequence
detection thermal cycler (Applied Biosystems, Foster City, CA), or the ViiA Real-Time
PCR system (Applied Biosystems) with SYBR Green PCR Master Mix (QIAGEN) using
primers listed in Table S11. A negative control (water instead of template) was used in each
real-time plate for each primer set. All real-time experiments were performed in triplicate.
Baseline and threshold values (Ct) were obtained using ABI 7500 Prism and the relative
expression of mRNA was calculated using the comparative 2−11Ct method (Livak &
Schmittgen, 2001). Expression was normalized to the housekeeping gene ribosomal protein
L32 (RPL32). Statistical analyses were performed using GraphPad Prism v.6.01 software
(GraphPad Software, Inc., San Diego, CA). Student’s t -test or Mann–Whitney-Wilcoxon
tests were used to assess the statistical significance of all the direct comparisons.
Cell proliferation assays
Proliferation assays were performed using an xCELLigence real-time cell analyzer (RTCA)
DP instrument (ACEABiosciences, SanDiego, CA). This system employs sensor impedance
technology to quantify the status of the cell using a unit-less parameter termed the cell
index (CI). The CI represents the status of the cell based on themeasured relative changes in
electrical impedance that occur in the presence and absence of cells in the wells (generated
by the software, according to the formula CI = (Zi–Z0)/15 , where Z i is the impedance
at an individual point of time during the experiment and Z0 the impedance at the start
of the experiment). Impedance is measured at three different frequencies (10, 25 or 50
kHz). Briefly, 5×103 cells were trypsinized and seeded into a 96 well plate (E-plate) and
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grown for 48 h in 150 µl growth media. Cell index was measured every 15 min and all
experiments were performed in triplicate, with at least three independent repeats. Because
cells did not attach well to the gold microelectrodes of the xCELLigence instrument,
LNCaP proliferation was quantified by measuring the cleavage of WST-1 (Roche, Basel,
Switzerland). Briefly, 5×104 cells/ well were seeded in 96-well plates (BD Biosciences,
Franklin Lakes, NJ, USA) and propagated for 72 h in complete medium. To determine cell
number, absorbance was measured using the FLUOstar Omega spectrophotometer (BMG,
Ortenberg, Germany) at 440 nm using a reference wavelength of 600 nm. All proliferation
experiments were performed independently three times, with 8 replicates each.
Cell viability assay
LNCaP and PC3 vector or GHSROS over-expressing cells (5,000 cells/well) were seeded in
96-well plates (BD Biosciences) and propagated overnight in complete medium. LNCaP
cells were treated with standard doses of test compounds in both charcoal stripped FCS
(CSS) or 2% FCS. PC3 cells were treated with increasing doses of docetaxel in 2% FCS.
After a 96-hour period cell viability was measured using a WST-1 cell proliferation assay
(Roche, Nonnenwald, Penzberg, Germany) according to the manufacturer’s instructions.
All viability experiments were performed independently three times, with 4 replicates each.
Cell migration assays
Migration assays were performed using an xCELLigence RTCA DP instrument (ACEA
Biosciences). Briefly, 5×104 cells/well were seeded on the top chamber in 150µl serum-free
media. The lower chamber contained 160 µl media with 10% FCS as a chemo-attractant.
Cell index was measured every 15 min for 24 h to indicate the rate of cell migration to the
lower chamber. All experiments were performed in triplicate with at least 3 independent
repeats. Because cells did not attach well to the gold microelectrodes of the xCELLigence
instrument, LNCaPs migration was assessed using a transwell assay. Briefly, 6×105 cells
were suspended in serum-free medium and added to the upper chamber of inserts coated
with a polycarbonate membrane (8 µm pore size; BD Biosciences). Cells in 12-well plates
were allowed to migrate for 24 h in response to a chemoattractant (10% FBS) in the lower
chamber. After 24 h, cells remaining in the upper chamber were removed. Cells that had
migrated to the lower surface of the membrane were fixed with methanol (100%) and
stained with 1% crystal violet. Acetic acid (10%, v/v) was used to extract the crystal violet
and absorbance was measured at 595 nm. Each experiment consisted of three replicates
and was repeated independently three times.
Locked nucleic acid-antisense oligonucleotides (LNA-ASO)
Two distinct Locked nucleic acid (LNA) ASOs, RNV104L and RNV124, complementary
to different regions of GHSROS (see Fig. S6), were designed in-house and synthesized
commercially (Exiqon, Vedbæk, Denmark). The ASOs contained two consecutive LNA
nucleotides at the 5′-end and three consecutive LNA nucleotides at the 3′-end –in line
with gapmer design principles. The LNA ASO sequences were as follows: scrambled
control sequence: 5′-GC TTCGACTCGTAATCACCTA-3′; RNV124 (underlined bases
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denote LNA nucleotides): 5′-ATAA ACCTGCTAGTGTCCTCC-3′; RNV104L: 5′-
GTTAACTTTCTTCTTCCTTG-3′. Lyophilized oligonucleotides were resuspended in
ultrapure H2O (Invitrogen) and stored as a 100 µM stock solution at −20 ◦C. Briefly,
LNA-ASOs were diluted to 20 µM in OptiMEM I Reduced Serum Medium (Invitrogen)
and cultured cells were transfected according to the manufacturer’s instructions. Cultured
cells were incubated at 37 ◦C in 5% CO2 for 4 h, before 500 µl growth medium, containing
30% FCS, was added to the serum-free medium. The cells were transfected for 24–72 h and
GHSROS levels assessed by qRT-PCR.
Mouse subcutaneous in vivo xenograft models
All mouse studies were carried out with approval from the University of Queensland and
the Queensland University of Technology Animal Ethics Committees. PC3-GHSROS,
PC3-vector, DU145-GHSROS, DU145-vector, LNCaP-GHSROS, and LNCaP-vector cell
lines were injected subcutaneously into the flank of 4–5-week-old male NSG mice (Shultz
et al., 2005) (obtained from Animal Resource Centre, Murdoch, WA, Australia). Cells were
injected in a 1:1 ratio with growth factor-reduced Matrigel (Thermo Fisher) (n = 8–10
per cell line) and tumors measured twice weekly with digital calipers (ProSciTech, Kirwan,
QLD, Australia). Neither randomization nor blinding for animal use was performed
because we commercially obtained these mice with the same genetic background. Animals
were euthanized once tumor volume reached 1,000 mm, or at other ethical endpoints. At
the experimental endpoint, the primary tumor was resected, divided in half, snap frozen
and stored at −80 ◦C.
Histology and immunohistochemistry
For histological analysis, cryosections (6–10 µm thick) were prepared using a Leica
CM1850 cryotome (Wetzlar, Germany). Sections were collected onto warm, charged
Menzel Superfrost slides (Thermo Fisher), fixed in ice-cold 100% acetone, air dried and
stored at −80 ◦C. For immunohistochemistry, tissues were fixed in paraformaldehyde
and dehydrated through a graded series of ethanol and xylene, before being embedded in
paraffin. Sections (5µm)weremounted on to glassMenzel Superfrost slides (ThermoFisher
Scientific). Immunohistochemistry was performed using antibodies for the proliferation
marker Ki67 (rabbit anti-human Ki67, Abcam, Cambridge, UK) and for the infiltration of
murine blood vessels using rabbit anti-murine CD31 antibody (Abcam). Tissue sections
were incubated with HRP-polymer conjugates (SuperPicture, Thermo Fisher Scientific),
and incubated with the chromagen diaminobenzidine (DAB) (Dako, Glostrup, Denmark),
as per manufacturer’s specifications. Slides were counterstained with Mayer’s hematoxylin,
dehydrated, and mounted with coverslips using D.P.X neutral mounting medium (Sigma
Aldrich). All sections were counterstained with Mayer’s hematoxylin (Sigma Aldrich) and
mounted with coverslips using D.P.X with Colourfast (Fronine, ThermoFisher Scientific).
RNA-sequencing of GHSROS overexpressing PC3 and LNCaP cells
Total RNAwas extracted from in vitro culturedPC3-GHSROS cells and controls, as outlined
above. RNA purity was analysed using an Agilent 2100 Bioanalyzer, and RNA with an RNA
Integrity Number (RIN) above 7 used for RNA-sequencing (RNA-seq). Strand-specific
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RNA-seq was performed by Macrogen, South Korea. A TruSeq stranded mRNA library
(Illumina) was constructed and RNA sequencing performed (50 million reads) on a HiSeq
2000 instrument (Illumina) with 100 bp paired end reads. For the LNCaP-GHSROS
xenograft tumors and controls (empty vector control lentiviral constructs), total RNA
and RNA purity was extracted analysed as above. Strand-specific RNA-seq was performed
by the South Australian Health and Medical Research Institute (SAHMRI, Adelaide,
SA, Australia). A TruSeq stranded mRNA library (Illumina) was constructed and RNA
sequencing performed (35million reads) on aNextseq 500 instrument (Illumina) with 75bp
single end reads. See Supplementary information for details regarding RNA-seq analysis.
Raw and processed RNA-sequencing (transcriptome) data have been deposited in Gene
Expression Omnibus (GEO) with the accession codes GSE86097 (GHSROS overexpression
in cultured PC3 cells) and GSE103320 (GHSROS overexpression in LNCaP xenografts).
Gene Ontology (GO) term analyses and Oncomine Concept analysis
Gene Ontology (GO) term analyses were performed using DAVID (Database for
Annotation, Visualization and Integrated Discovery) (Da Huang, Sherman & Lempicki,
2009). Briefly, to test for enrichment we interrogated DAVID’s GO FAT database with
genes differentially expressed in PC3-GHSROS cells. The DAVID functional annotation
tool categorizes GO terms and calculates an ‘enrichment score’ or EASE score (a modified
Fisher’s exact test-derived P-value). Categories with smaller P-values (P ≤ 0.01) and larger
fold-enrichments (≥2.0) were considered interesting and most likely to convey biological
meaning.
To perform Oncomine meta-analysis, genes differentially expressed in PC3-GHSROS
were separated into ‘over-expressed’ and ‘under-expressed’ gene sets. The Oncomine
database (Hodes et al., 2007) was interrogated by importing these genes, and enriched
concepts were generated and ordered by P-values (calculated using Fisher’s exact test).
Only datasets with an odds ratio≥ 3.0 and a P- value≤ 0.01were retained. The datasets were
exported as nodes and edges for network visualization in Cytoscape (Shannon et al., 2003)
(v3.4.0). The network layout and node position were generated using the Force-Directed
Layout algorithm (Suderman & Hallett, 2007), with odds ratio as the leading parameter for
the edge weight. Using our custom concept generated lists, we next sought to assess the
differential expression of our gene lists in two prostate cancer microarray datasets: Grasso
(Grasso et al., 2012) (59 localized and 35 metastatic prostate tumors) and Taylor (Taylor et
al., 2010) (123 localized and 27 metastatic prostate tumors). Differentially expressed genes
were ranked and results exported as fold change (log2 transformed, median centered).
Data was filtered for significance with P-value set at ≤0.05 and Benjamini–Hochberg false
discovery rate (FDR)Q-value (Benjamini & Hochberg, 1995) at≤ 0.25; a threshold deemed
suitable to find biologically relevant transcriptional signatures (Luck et al., 2014; Simola et
al., 2013).
LP50 prostate cancer cell line AR knockdown microarray
Publicly available Affymetrix HG-U133 Plus 2.0 microarray data (NCBI GEO accession
no. GSE22483) from a substrain of the LNCaP cell line: the androgen-independent late
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passage LNCaP cells (LP50) was interrogated. This cell line was subjected to androgen
receptor (AR) knockdown by shRNA (Gonit et al., 2011). The array (n = 2, of AR shRNA
and scrambled control) was normalized to housekeeping genes using the Affymetrix Gene
Chip Operating System v1.4 (Gonit et al., 2011). Prior to differential expression analysis,
the probe set was pre-filtered, using the R statistical programming language, as follows:
probes with mean expression values in the lowest 20th percentile of the array was removed.
Differential expression was determined by the R package ‘limma’ (Ritchie et al., 2015) and
probes with a Benjamini–Hochberg adjusted P-value (Q; BH-FDR) ≤ 0.05 considered
significant. Gene annotations were obtained using the R/Bioconductor packages ‘Biobase’
(Robinson & Oshlack, 2010) and ‘GEOquery’ (Davis & Meltzer, 2007).
Survival analysis in clinical gene expression datasets
Two datasets were interrogated: Taylor (Taylor et al., 2010) and TCGA-PRAD from The
Cancer Genomics Atlas (TCGA) consortium, which contains tumors from patients with
moderate- (∼39% Gleason score 6 and 3 + 4) and high- (∼61% Gleason 4+3 and Gleason
score 8-10) risk localized prostate carcinoma (Cancer Genome Atlas Research Network,
2015). Briefly, in the case of TCGA-PRAD, the UCSC Xena Browser (Casper et al., 2015)
was used to obtain normalized gene expression values, represented as log2 (normalized
counts+1), from the ‘TCGA TARGET GTeX’ dataset consisting of ∼12,000 tissue samples
from 31 cancers (Vivian et al., 2017). To obtain up-to-date overall survival (OS) and
disease-free survival (DFS) information, we manually queried cBioPortal for Cancer
Genomics (Cerami et al., 2012;Gao et al., 2013) (last accessed 05.08.16). See Supplementary
information for details.
Statistical analyses
Data values were expressed as mean ± s.e.m. of at least two independent experiments
and evaluated using Student’s t -test for unpaired samples, or otherwise specified. Mean
differences were considered significant when P ≤ 0.05. Q-values denote multiple testing
correction (Benjamini–Hochberg) adjusted P-values (Benjamini & Hochberg, 1995).
Normalized high-throughput gene expression datawere analyzed using LIMMA, employing
a modified version of the Student’s t -test (moderated t -test) where the standard errors are
reduced toward a common value using an empirical Bayesian model robust for datasets
with few biological replicates (Ritchie et al., 2015). Statistical analyses were performed
using GraphPad Prism v.6.01 software (GraphPad Software, Inc., San Diego, CA), or the R
statistical programming language.
RESULTS
GHSROS is expressed in prostate cancer
Microarrays and RNA-sequencing are commonly used to assess the expression of genes.
LncRNAs are often expressed at orders of magnitude lower than protein-coding transcripts,
however,making themdifficult to detect (Derrien et al., 2012;Ruiz-Orera et al., 2014;Kutter
et al., 2012;Cabili et al., 2011;Necsulea et al., 2014;Wang et al., 2011). Interrogation of exon
arrays harboring four different strand-specific probes against GHSROS demonstrated that
Thomas et al. (2021), PeerJ, DOI 10.7717/peerj.10280 9/29
the lncRNA is actively transcribed, although expressed at low levels in cancer cell lines
and tissues (Fig. S1), consistent with previous observations from Northern blotting and
RT-PCR experiments (Whiteside et al., 2013). The low expression across the GHSROS and
GHSR loci in RNA-seq datasets is illustrated in Fig. S2. Collectively, these data demonstrate
that it is currently not possible to detect GHSROS in public genome-wide gene expression
datasets.
We next evaluated GHSROS expression in a qRT-PCR tissue array of 18 cancers. This
analysis revealed particularly high GHSROS expression in lung tumors, as previously
reported (Whiteside et al., 2013), and elevated expression in prostate tumors (Fig. 1B).
Analysis of additional prostate tissue-derived cDNA arrays revealed that GHSROS could be
detected in approximately 41.7% of all normal prostate tissues (n= 24), 55.7% of tumors (n
= 88), and 58.1% of other prostatic diseases (e.g., prostatitis; n= 31) (Table S1). GHSROS
was highly expressed by a subset of prostate tumors (∼11.4%; Z -score > 1) (Fig. 1C) and
elevated in tumors with Gleason scores 8–10 (Fig. S3; Table S1; Mann–Whitney-Wilcoxon
test P = 0.0021). To expand on these observations, we examined an independent cohort of
eight normal prostate tissue specimens and 28 primary tumors with high Gleason scores
(18 of which had metastases at biopsy). Similarly, GHSROS expression was significantly
elevated in tumors compared to normal prostate tissue (Mann–Whitney-Wilcoxon test,
P = 0.0070) (Fig. 1D; Fig. S4; Table S2).
As the functional thresholds of long non-coding RNAs are difficult to gauge and likely to
be cell specific (Geisler & Coller, 2013), we identified cell lines with a range of endogenous
GHSROS expression. Compared to the RWPE-1 benign prostate-derived cell line, higher
expression was observed in the PC3 (P = 0.00040, Student’s t- test) (Fig. 1E) and DuCaP
prostate cancer cell lines (P = 0.0024), and expression was similar to RWPE-1 in the DU145
(P = 0.29) and LNCaP prostate cancer cell lines (P = 0.49). We also assessed the expression
of GHSROS in patient-derived xenografts (PDXs). Compared to the RWPE-1 cell line,
GHSROS was significantly upregulated (P ≤ 0.05) in 4/6 of the LuCaP series of PDX lines
(Nguyen et al., 2017) and in the BM18 femoral metastasis-derived androgen-responsive
PDX line (McCulloch et al., 2005) (P = 0.0005) (Fig. 1E).
GHSROS promotes growth and motility of prostate cancer cells in vitro
To gain insights into GHSROS, we assessed its function in three prostate-derived cell
lines by stably overexpressing the lncRNA in PC3, DU145, and LNCaP cells (denoted
PC3-GHSROS, DU145-GHSROS, and LNCaP-GHSROS) (Fig. S5). Cell proliferation over
72 h (measured by a xCELLigence real-time cell analysis instrument) was increased in
PC3 (P = 0.029, Student’s t -test) and DU145 (P = 0.026) GHSROS-overexpressing cells
(Figs. 2A, 2B). LNCaP cells did not attach well to the gold electrodes of the xCELLigence
instrument (data not shown), and we therefore utilized a WST-1 assay to assess this cell
line. Similar to PC3 and DU145 cells overexpressing GHSROS, proliferation was also
increased in LNCaP-GHSROS cells at 72 h (P = 0.040) (Fig. 2C). GHSROS overexpression
also increased the rate of cell migration in PC3 (P = 0.0064, Student’s t -test), DU145
(P = 0.017), and LNCaP cell lines (P = 0.00020) over 24 h (Figs. 2D, 2E, 2F) (where
LNCaP was assessed by a standard transwell migration assay; PC3 and DU145 using the
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Figure 2 GHSROS promotes human prostate cancer cell line growth andmotility in vitro. (A, B, C)
Increased proliferation in GHSROS-overexpressing cells. PC3 and DU145 cells were assessed using an
xCELLigence real-time cell analyzer for 72 h; LNCaP using a WST-1 assay at 72 h. Vector denotes empty
control plasmid. Mean± s.e.m. (n= 3). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, Student’s t -test. (D, E,
F) Increased migration in GHSROS-overexpressing cells. PC3 and DU145 cells were assessed using an
xCELLigence real-time cell analyzer for 24 h; LNCaP using a transwell assay (at 24 h; n= 3). Parameters
and annotations as in (A). (G) Prediction of GHSROS RNA secondary structure. The location of locked
nucleic antisense oligonucleotides (LNA ASOs) that target the lncRNA are shown in red. MFE denotes
minimum free energy. (H) LNA ASOs reduced GHSROS expression in PC3 cells (measured 48 h post-
transfection). Fold-enrichment of GHSROS normalized to RPL32 and compared to scrambled control (n
= 3). Parameters and annotations as in (A). (i) GHSROS knockdown reduces PC3 proliferation (n= 3).
Parameters and annotations as in (A). GHSROS knockdown reduces PC3 migration. (J) RNV124 reduced
cell migration at 18 h (n= 3). Parameters and annotations as in (C).
Full-size DOI: 10.7717/peerj.10280/fig-2
xCELLigence instrument). To confirm the in vitro functional effects of GHSROS, we
designed locked nucleic antisense oligonucleotides (LNA-ASOs) to strand-specifically
silence endogenous GHSROS expression (Fig. 2G; Fig. S6). Two LNA-ASOs targeting
distinct regions ofGHSROS, RNV124 andRNV104L, independently reduced the expression
of GHSROS (percentage knockdown of∼63% and∼71%, respectively) in native PC3 cells
48 h post transfection compared to scrambled control (P = 0.0002 and P = 0.0001,
Student’s t -test) (Fig. 2H). Moreover, GHSROS knockdown attenuated cell proliferation
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Figure 3 GHSROSmediates cell survival and resistance to the cytotoxic drug docetaxel. (A) Viability
of GHSROS-overexpressing LNCaP cells under different culture conditions. Cell number was assessed
using WST-1. Cells were treated with enzalutamide (ENZ; 10 µM) or docetaxel (DTX; 5 nM) for 96 h
and grown in either 2% FBS or 5% charcoal stripped serum (CSS) RPMI-1640 media (n= 3). Mean
± s.e.m. *P ≤ 0.05, ***P ≤ 0.001, Student’s t -test. (B) GHSROS expression of native PC3 and LNCaP
cells treated with docetaxel. Cells were grown in RPMI-1640 media with 2% FBS and treated with 1–20
nM docetaxel (DTX) for 48 h (n= 3). Fold-enrichment of GHSROS normalized to RPL32 and compared
to empty vector control. Parameters and annotations as in (A). (C) GHSROS and PSA (KLK3) expression
of native LNCaP cells treated with ENZ (10 µM in 2% FBS or 5% CSS RPMI-1640) or DTX (5 nM in 2%
FBS RPMI-1640) for 48 h (n= 3). Parameters and annotations as in (A).
Full-size DOI: 10.7717/peerj.10280/fig-3
(RNV124, P = 0.049; RNV104L, P = 0.030) (Fig. 2I) and migration in the PC3 cell line
over 18 h (RNV124, P = 0.0042) (Fig. 2J)—the reciprocal effects observed when GHSROS
was forcibly overexpressed.
GHSROS is associated with cell survival and resistance to the
cytotoxic drug docetaxel
Knockdown experiments also revealed that GHSROS protected PC3 prostate cancer cells
from death by serum starvation (Fig. S7). This observation led us to examine whether
GHSROS contributes to cell survival following chemotherapy. The current treatment of
choice for advanced, castration-resistant prostate cancer (CRPC; the fatal final stage of
the disease) after the failure of hormonal therapy is the cytotoxic drug docetaxel, a semi-
synthetic taxoid that induces cell cycle arrest. At the half maximal inhibitory concentration
(IC50) of docetaxel (5 nM for LNCaP (Gan et al., 2016)), survival was significantly increased
in GHSROS-overexpressing LNCaP cells (P ≤ 0.05, Student’s t -test) (Fig. 3A) after 96 h. A
similar, less pronounced response was observed in LNCaP cells treated with enzalutamide,
a hormonal therapy used to target the androgen receptor in metastatic, castration-resistant
tumors (Drake, Sharma & Gerritsen, 2014) (Fig. 3A).
Survival pathways are induced after docetaxel treatment in prostate cancer (Sonpavde
et al., 2015; Chandrasekar et al., 2015), and resistance may develop after chemotherapy
(acquired resistance) or exist in treatment-naïve patients (innate resistance) (Sonpavde
et al., 2015). The pronounced survival following docetaxel treatment in GHSROS-
overexpressing LNCaP cells led us to speculate that endogenous GHSROS expression
also contributed to drug resistance. Docetaxel significantly increased GHSROS expression
in native LNCaP and PC3 cells—in a dose-dependent manner and at concentrations both
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above and below their respective IC50 values (Fig. 3B). The lncRNA was not differentially
expressed in charcoal stripped serum (CSS), used to simulate androgen deprivation
therapy, or following treatment with enzalutamide (Fig. 3C). In agreement with previous
reports (Lee et al., 2014; Tran et al., 2009), the gene coding for prostate specific antigen
(PSA; KLK3) was downregulated by docetaxel and enzalutamide in LNCaP cells (-6.6-fold,
P = 0.00070, Student’s t -test) (Fig. 3C). Taken together, these data suggest that GHSROS
mediates tumor survival and resistance to the cytotoxic chemotherapy docetaxel.
GHSROS potentiates tumor growth in vivo
In order to firmly establish a role for GHSROS in tumor growth, we established
subcutaneous GHSROS-overexpressing androgen-independent (PC3 and DU145) and
androgen-responsive (LNCaP) cell line xenografts in NOD/SCID IL2R γ (NSG) mice.
Subcutaneous graft sites allow easy implantation and monitoring of tumor growth (using
calipers) (Lin et al., 2014)—ideal for exploring the role of a new gene such as GHSROS in
vivo. Overexpression of GHSROS in xenografts was confirmed post-mortem by qRT-PCR
(Fig. S8). Compared to vector controls, xenograft tumor volumes were significantly greater
at day 25 in PC3-GHSROS mice (P = 0.0040, Mann–Whitney-Wilcoxon test) and at day
35 in DU145-GHSROS mice (P = 0.0011) (Figs. 4A, 4B). While xenograft tumors were
not palpable in LNCaP-GHSROS mice in vivo, tumors were significantly larger by weight
post-mortem (at 72 days) (P = 0.042) (Fig. 4C)—with a size increase similar to that seen for
DU145-GHSROS xenografts (Fig. 4D). LNCaP-GHSROS tumors invaded the flank muscle
and the peritoneum (data not shown) and were more vascularized than control tumors
(observed grossly and estimated by CD31+ immunostaining) (Fig. 4G). Representative
Ki67 immunostaining for proliferating xenograft tumor cells is shown in Fig. 4H.
GHSROS modulates the expression of cancer-associated genes
Having established that GHSROS plays a role in regulating hallmarks of cancer—including
cell proliferation, invasion, and migration (Hanahan &Weinberg, 2011)—we sought to
determine the genes likely to mediate its function by examining the transcriptomes of
cultured PC3 cells and LNCaP xenografts overexpressing this lncRNA.
High-throughput RNA-seq of cultured PC3-GHSROS cells (∼50M reads) revealed
that 400 genes were differentially expressed (168 upregulated and 232 downregulated;
moderated t -test; cutoff set at log2 fold-change ±1.5, Q ≤0.05) (Table S3) compared
with empty vector control cells. Supporting our functional data, gene ontology analysis
(using DAVID) showed enrichment for processes such as epithelial structure maintenance,
response to hormone stimulus, steroid hormone stimulus, estradiol stimulus, response
to hypoxia, and drug response (Tables S4 and S5). Given that GHSROS is not readily
detectable by high-throughput sequencing and array technologies, we queried the 400
genes differentially expressed in PC3-GHSROS cells by Oncomine concept map analysis
(Hodes et al., 2007). Enriched Oncomine concepts included poor clinical outcome and
metastatic progression (Fig. 5A; Table S6).
Complementary lower-coverage (∼30M reads) RNA-seq data from LNCaP-GHSROS
xenografts demonstrated that a surprisingly large number of genes were differentially
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Figure 4 GHSROS promotes human prostate cancer cell line growth in vivo. (A) Time course for PC3-
GHSROS (n= 8) and vector control (n= 4) xenograft tumor volumes. (B) DU145-GHSROS (n= 6) and
vector control (n= 4). Mean± s.e.m. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, two-way ANOVA with Bon-
feronni’s post hoc analysis. Tumors were measured with digital calipers. (C) Tumor weights of LNCaP (
GHSROS-overexpressing n= 9, vector n= 8) or (D) DU145. *P ≤ 0.05, Mann–Whitney-Wilcoxon test.
(E) Size comparisons of DU145 (top panel) and (F) LNCaP (bottom panel) xenografts overexpressing
GHSROS or empty vector. (G) Representative morphology of LNCaP xenografts overexpressing GHSROS
or empty vector. Tissue was stained with hematoxylin and eosin (H&E), Masson’s Trichrome (MT; colla-
gen; blue) and CD31 (endothelial marker; brown immunoreactivity). Scale bar= 20 µm. (H) Representa-
tive Ki67 immunostaining of PC3 xenografts, DU145 xenografts, and LNCaP xenografts. Scale= 20 µm.
Full-size DOI: 10.7717/peerj.10280/fig-4
expressed (1,961 upregulated, 2,372 downregulated, moderated t -test; cutoff set at log2
fold-change ±1.5, Q ≤ 0.05) (Dataset S1). Selected genes with low expression counts
were validated by qRT-PCR (Fig. S9). In LNCaP-GHSROS xenografts, GHSROS-regulated
genes were enriched for the androgen response (gene set enrichment analysis; NES =
2.71, Q ≤ 0.001) (Fig. 5B), and included PSA (KLK3) (750.9-fold, Q= 3.6×10−6) and
transmembrane protease serine 2 (TMPRSS2) (335.4-fold, Q= 4.5×10−6) (Dataset S2).
We also observed downregulation of numerous genes associated with cell migration
and adhesion, epithelial–mesenchymal transition (EMT) (including ZEB1; -97.0-fold,
Q = 1.5× 10−5), and angiogenesis and vasculature development (Dataset S3). As
mentioned above, subcutaneous LNCaP-GHSROS xenografts infiltrated flank muscle
and the peritoneum and were more vascularized at 72 days post injection in NSG mice,
which may indicate that these invasive tumors may have undergone EMT and promoted
angiogenesis.
It is appreciated that the bone metastasis-derived, androgen-independent PC3 and the
lymph node metastasis-derived, androgen-responsive LNCaP prostate cancer cell lines
represent genetically and presumably metabolically distinct subtypes (Seim et al., 2017).
They are therefore useful for revealing broad, functional gene expression changes associated
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Figure 5 GHSROS overexpressionmodulates the expression of cancer-associated genes. (A)
Oncomine network representation of genes differentially expressed by cultured PC3-GHSROS cells
visualized using Cytoscape. Node sizes (gene overlap) reflect the number of genes (continued on next
page. . . )
Full-size DOI: 10.7717/peerj.10280/fig-5
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Figure 5 (. . .continued)
per molecular concept. Nodes are colored according to concept categories indicated in the left corner.
Edges connect enriched nodes (odds ratio ≥ 3.0) and darker edge shading indicates a higher odds ratio.
(B) Gene set enrichment analysis (GSEA) of genes differentially expressed by LNCaP-GHSROS xenografts
reveals enrichment for the androgen response. The normalized enrichment score (NES) and GSEA
false-discovery corrected P-value (Q) are indicated. (C) Venn diagram of differentially expressed genes
(DEG) in LNCaP-GHSROS and PC3-GHSROS cells. Symbols of 101 overlapping genes are indicated in
text boxes. (D) Interaction of 101 genes differentially expressed in PC3-GHSROS and LNCaP-GHSROS
cells (see (C)). Lines represent protein-protein interaction networks from the STRING database. Genes
induced (red) or repressed (blue) by GHSROS-overexpression are indicated. (E) Gene expression scatter
plot comparing GHSROS-overexpressing PC3 and LNCaP cells. Differentially expressed genes (DEGs)
in both datasets shown in red (induced) and blue (repressed); of which ≥ 8-fold (log2 cutoff at−3
and 3) DEGs are highlighted by a green box. (F) Heat map of gene expression in GHSROS-perturbed
cells. Each row shows the relative expression of a single gene and each column a sample (biological
replicate). Fold-enrichment of each gene normalized to RPL32 and compared to empty vector control
(overexpression) or scrambled control (LNA-ASO knockdown). Fold-changes were log2-transformed
and are displayed in the heat map as the relative expression of a gene in a sample compared to all other
samples (Z -score).
with aggressive disease in forced overexpression and knockdown experiments. Despite the
differences between these cell lines, a quarter (25.3%; 101) of genes differentially expressed
by PC3 cells overexpressingGHSROSwere also differentially expressed by LNCaP-GHSROS
cells (Fig. 5C) (P = 0.000020, hypergeometric test). These genes represent candidate
mediators of GHSROS function.
We interrogated the STRING database (Gao et al., 2013) to reveal protein interactions
between the 101 genes regulated byGHSROS in both cell lines. A number of genes associated
with cell–cell adhesion, migration, and growth were connected, indicating functional
enrichment of these proteins in GHSROS-overexpressing prostate cancer cells (Fig. 5D).
This included increased expression of epithelial cadherin (CDH1), occludin (OCLN ), and
claudin-7 (CLDN7); and decreased contactin 1 (CNT1), noggin (NOG), and transforming
growth factor beta induced (TGFBI ) in GHSROS-overexpressing cells. Of note, increased
CDH1 expression is associated with exit from EMT and growth of aggressive, metastatic
prostate tumors (Putzke et al., 2011). A second, interesting upregulated network included
anterior gradient 2 (AGR2) and trefoil factors 1 and 2 (TFF1 and TFF2). Trefoil factors
are small proteins associated with mucin glycoproteins. Their expression is increased
in castration-resistant prostate cancer (CRPC) and may facilitate the acquisition of
hormone independence (Vestergaard et al., 2006; Kani et al., 2013). Similarly, AGR2 has
been associated with the propensity of a number of aggressive tumor types to metastasize,
including prostate cancer (Zweitzig et al., 2007).
Ten out of the 101 genes were differentially expressed in metastatic tumors compared to
primary tumors in two clinical prostate datasets: Grasso (Taylor et al., 2010) (59 localized
and 35metastatic prostate tumors) and Taylor (Benjamini & Hochberg, 1995) (123 localized
and 27 metastatic prostate tumors) (Tables S7 and S8) (Q ≤ 0.25, moderated t -test).
DIRAS1, FBXL16, TP53I11, TFF2, and ZNF467 were upregulated in bothmetastatic tumors
and GHSROS-overexpressing PC3 and LNCaP cells, while AASS, CHRDL1, CNTN1, IFI16,
andMUM1L1 were downregulated. We investigated whether the expression of these genes
contributes to adverse disease outcome by assessing survival in two independent datasets:
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the Taylor dataset and TCGA-PRAD. The latter is a dataset of localized prostate tumors
generated by The Cancer Genomics Atlas (TCGA) consortium (Casper et al., 2015; Cancer
Genome Atlas Research Network, 2015). As overall survival data was available for a small
number of patients in these datasets, we assessed disease-free survival (relapse). Relapse
is a suitable surrogate for overall survival in prostate cancer given that recurrence of
disease would be expected to contribute significantly to mortality, and metastatic disease
is incurable. Unsupervised k-means clustering was employed to divide each dataset into
two groups based on gene expression alone. Two genes, zinc finger protein 467 (ZNF467 ;
which was induced by forced GHSROS-overexpression) and chordin-like 1 (CHRDL1;
which was repressed), correlated with relapse in both datasets (Table S9). Chordin-like 1 is
a negative regulator of bone morphogenetic protein 4-induced migration and invasion in
breast cancer (Cyr-Depauw et al., 2016). It was downregulated in GHSROS-overexpressing
cell lines and in metastatic tumors compared to localized tumors in the Taylor and Grasso
datasets. Interrogation of the Chandran prostate cancer dataset (60 localized tumors and 63
adjacent, normal prostate) (Chandran et al., 2005) suggests that CHRDL1 is downregulated
by prostate tumors in general. CHRDL1 expression stratified the Taylor (N = 150; 27
metastatic tumors) dataset into two groups with a significant, 438-day difference in
overall disease-free survival (relapse; Cox P = 0.0062, absolute hazard ratio (HR) =
2.5). A statistically significant, yet clinically negligible, difference in relapse (9 days; Cox
P = 0.0071, absolute HR = 1.8) was observed in the TCGA-PRAD dataset (N = 489;
no metastatic tumors) (Table S9). Survival analysis P-values (Kaplan–Meier and Cox
proportional-hazard) and hazard ratios indicate whether there is a significant difference
between two groups, but not the degree of difference. Evaluating statistically significant
differences in survival (e.g., in days) between groups is therefore subjective. Given these
data, we propose that CHRDL1 may play an important role in metastatic tumors.
In contrast to CHRDL1, ZNF467 stratified patients into clusters with an obvious
difference in overall median survival (relapse) between groups in both the Taylor (697
days; Cox P = 0.0039, HR= 2.7) and TCGA-PRAD datasets (139 days; Cox P = 0.000026,
HR = 2.5) (Table S9). ZNF467 has not been functionally characterized, however, a recent
study suggests that it is a transcription factor which clusters in close proximity to the
androgen receptor in a network associated with breast cancer risk (Castro et al., 2016),
indicating that ZNF467 and AR regulate similar pathways. Clustering of patients into
groups of either low or high ZNF467 expression revealed that elevated expression of the
gene associated with a worse relapse outcome (Fig. S10A–Fig. S10C). In agreement, ZNF467
gene expression can distinguish low (≤6) from high (≥8) Gleason score prostate tumors
in a Fred Hutchinson Cancer Research Center prostate cancer dataset (381 localized and
27 metastatic prostate tumors) (Jhun et al., 2017). ZNF467 expression is also elevated in
chemotherapy-resistant ovarian cancer (Zhu et al., 2015) and breast cancer (Davies et al.,
2014) cell lines.
The 101 GHSROS-regulated genes were visualized in a scatter plot to reveal genes with
particularly distinct (here ∼8-fold) differential expression in GHSROS-overexpressing
prostate cancer cell lines –putative fundamental drivers of the observed tumorigenic
phenotypes. This revealed that PPP2R2C (Fig. 5E), a gene encoding a subunit of the
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holoenzyme phosphatase 2A (PP2A) (Bluemn et al., 2013; Gonzalez-Alonso et al., 2015),
was downregulated by forced overexpression of GHSROS. In the PC3-GHSROS RNA-seq
dataset, PPP2R2C was the third most downregulated gene (−29.9-fold, moderated t -test
Q= 3.4×10−10) (Table S3). Consistently, forced overexpression or knockdownofGHSROS
in prostate cancer cell lines reciprocally regulated endogenous PPP2R2C expression (Fig.
5F; Figs. S9 and S11).
We observed thatGHSROSwas also able to reciprocally regulate androgen receptor (AR)
expression in some prostate cancer cell lines (downregulated uponGHSROS overexpression
in PC3 and LNCaP; upregulated upon GHSROS knockdown in DUCaP) (Fig. 5F). LNCaP-
GHSROS xenografts showed a variable AR expression pattern, which may be linked to
differences in available androgen, however, PPP2R2C expression was still significantly
repressed in vivo (−3.7-fold, Student’s t -test P = 7.9×10−3) (Fig. S9). Similarly, while
AR could not be detected in DU145 cells, GHSROS-overexpression decreased PPP2R2C
expression in this cell line (Fig. 5F). The androgen receptor is also expressed by ovarian
and lung cancer tumors and cell lines (Zhu et al., 2017; Harlos et al., 2015). Forced
overexpression of GHSROS in the A549 lung adenocarcinoma cell line decreased AR
and PPP2R2C expression (Student’s t -test, P ≤ 0.0001). GHSROS knockdown in the ES-2
ovarian clear cell carcinoma cell line, which does not express PPP2R2C, increased the
expression of AR (Student’s t -test, P = 0.0029 and P = 0.0022) (Fig. 5F; Fig. S11).
DISCUSSION
Recent work suggests that a small proportion (∼3%) of long non-coding RNA genes are
dysregulated in tumors and mediate cell growth (Liu et al., 2017). Herein, we demonstrate
that the lncRNA GHSROS is one such gene. GHSROS expression is elevated across many
different cancers, suggesting that it is a so-called pan-cancer lncRNA (Chiu et al., 2018;
Cabanski et al., 2015). In prostate cancer GHSROS is detectable in normal tissue and
expressed at higher levels in a subset (∼10%) of tumors. We have yet to determine which
subgroups of prostate cancer demonstrate elevated GHSROS, however.
From assessing the function of GHSROS in immortalized prostate cancer cell lines
we observed that forced overexpression of GHSROS enhances in vivo tumor growth
and invasion, and in vitro cell viability and motility. We also demonstrate that forced
overexpression of GHSROS facilitates survival and recalcitrance to the cytotoxic
chemotherapy drug docetaxel. Critically, we show that endogenous GHSROS is elevated
following docetaxel treatment. Docetaxel is commonly prescribed for late-stage, metastatic
CRPC patients, but large, randomized trials suggest that it is also effective against recently-
diagnosed, localized prostate tumors (Puente et al., 2017). These data suggest thatGHSROS
acts as a cell survival factor in prostate cancer. While the underlying mechanisms are
unknown, two genes associated with chemotherapy resistance, ZNF467 and PPP1R1B (also
known asDARPP-32), were upregulated in PC3 and LNCaP cells overexpressing GHSROS.
PPP1R1B is a potent anti-apoptotic gene which confers resistance in cancer cell lines to
several chemotherapeutic agents when overexpressed (Belkhiri, Zhu & El-Rifai, 2016).
The expression and function of GHSROS in prostate cancer suggests that it belongs to a
growing list of lncRNAs that function as bona fide oncogenes. Notable examples associated
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with aggressive cancer and adverse outcomes include HOTAIR (HOX transcript antisense
RNA), which is upregulated in a range of cancers (Huarte, 2015), and the prostate cancer-
specific SCHLAP1 (SWI/SNF Complex Antagonist Associated With Prostate Cancer 1)
(Prensner et al., 2013). To better understand how GHSROS mediates its effects in prostate
cancer, we examined transcriptomes of prostate cancer cell lines with forced GHSROS
overexpression: PC3 cells in culture (in vitro) and subcutaneous LNCaP xenografts in mice
(in vivo). The 101 common differentially expressed genes included several transcription
factors with established roles in prostate cancer and genes associated with metastasis
and poor prognosis. Our study not only highlights genes modulated by GHSROS, but also
genes (such as ZNF467, CHRDL1, and PPP2R2C) that may be generally relevant to prostate
cancer progression.
Reactivation of the androgen receptor (AR) has long been considered a seminal event;
supporting renewed tumor growth in a majority of metastatic CRPC patients (Ferraldeschi
et al., 2015;Wyatt & Gleave, 2015). However, it is now increasingly recognized that, similar
to other endocrine-related cancers, several subtypes of prostate cancer exist (Tosoian
& Antonarakis, 2017; Shoag & Barbieri, 2016; Dagogo-Jack & Shaw, 2018). These include
subtypes characterized by androgen pathway-independent growth (Bluemn et al., 2013;
Wyatt & Gleave, 2015; luemn et al., 2017). In this context, our results on PPP2R2C, a
gene which encodes a PP2A substrate-binding regulatory subunit, is of interest. We
demonstrate that PPP2R2C expression in prostate cancer cell lines is repressed by forced
GHSROS overexpression and increased by GHSROS knockdown. There is emerging
evidence that inactivation of PP2A mediates CRPC in a subset of patients who display
resistance to AR-targeting therapies (Bluemn et al., 2013; Gonzalez-Alonso et al., 2015).
Loss of PPP2R2C expression alone is thought to reprogram prostate tumors towards
AR pathway-independent growth and survival (Bluemn et al., 2013). Several independent
lines of evidence suggest that PPP2R2C is a critical tumor suppressor involved in many
cancers. Loss of PPP2R2C expression has been attributed to esophageal adenocarcinoma
tumorigenesis (Peng et al., 2017), and PPP2R2C downregulation by distinct microRNAs
positively correlates with increased proliferation of cultured cancer cells derived from
the prostate (Bi et al., 2016), nasopharynx (Yan et al., 2017), and ovary (Wu et al., 2016).
PPP2R2C also has a classical growth-inhibiting tumor suppressor role in brain cancers
(Fan et al., 2013). A subtype of medulloblastoma, pediatric brain tumors, are characterized
by high expression of the chemokine receptor CXCR4 and concordant suppression
of PPP2R2C (Sengupta et al., 2012). Similarly, the gene is ablated in A2B5+ glioma
stem-like cells, a population which mediates a particularly aggressive chemotherapy-
resistant glioblastoma phenotype (Auvergne et al., 2013). Although seemingly paradoxical,
GHSROS repression of AR and PPP2R2C in prostate cancer cell lines can be rationalized.
Knockdown of PPP2R2C using small interfering RNA in cultured LNCaP and VCaP
cells did not alter the expression of AR (Bluemn et al., 2013). In contrast, AR knockdown
in androgen-independent LP50 cells (Gonzalez-Alonso et al., 2015) (a cell line derived
from LNCaP) markedly decreased PPP2R2C expression (Fig. S12)—suggestive of an
adaptive response to loss of androgen receptor expression (and function). Precisely how
GHSROS mediates PPP2R2C downregulation and its effects on tumor growth remains
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to be determined, however, GHSROS is the first lncRNA shown to downregulate this
critical tumor suppressor, suggesting a role in adaptive survival pathways and CRPC
development. Taken together, we speculate that GHSROS primes prostate tumors for
androgen receptor-independent growth.
In this study, the growth of GHSROS-overexpressing prostate cancer cell lines was
assessed using subcutaneous prostate cancer cell lines xenografts. We appreciate that other
models (including orthotopic xenografts) are critical for firmly establishing roles for a gene
in cancer processes, including invasion and metastasis (Sonpavde et al., 2015), and we will
assess these in a future study. An additional limitation to the present study is the relatively
high levels of ectopically expressed GHSROS in our cell line models. To complement our
overexpression studies, functional assays using modified ASOs in a range of prostate cell
lines and patient-derived xenografts (PDX) should be conducted in vitro and in vivo.
We recently performed in vivo experiments using LNA ASOs targeting GHSROS and
observed no signs of toxicity or weight loss in mouse models (Thomas et al., unpublished
data). This is similar to findings with other LNA ASOs of comparable lengths (16-mer
to 21-mer) (Chi et al., 2005; Emmrich et al., 2009). The interaction between GHSROS and
genomic regions, proteins, and other RNA transcripts also requires further elucidation.
While this study firmly establishes that GHSROS plays a role in prostate cancer, the
mechanism by which it reprograms gene expression remains unknown. LncRNAs are now
considered critical components of the cellular machinery (Mattick & Rinn, 2015). Unlike
protein-coding genes, which typically require sequence conservation to maintain function,
the mechanisms of action of lncRNAs are usually not obvious and uncovering their precise,
sometimes subtle, function remains a challenge (Mattick & Rinn, 2015). For example,
some lncRNAs modulate the epigenetic regulation of gene expression and interact with
chromatin, acting as scaffolds to guide other molecules (including RNA, proteins, and
epigenetic enzymes) to influence gene expression (Mattick & Rinn, 2015; Huarte, 2015).
Although cancers are highly heterogeneous diseases and few therapies target molecular
phenotypes, lncRNAs provide a largely untapped source for newmolecular targets (Huarte,
2015). Here, we developed antisense oligonucleotides targetingGHSROS and assessed them
in cultured cancer cells. We are currently refining our LNA oligonucleotides and their
delivery for targeting in vivo xenografts and prostate cancer patient-derived organoids
in order to further assess their clinical potential. Targeting GHSROS may present an
opportunity for clinical intervention, however, it is appreciated that translational and
regulatory challenges exist for oligonucleotide therapies (Stein & Castanotto, 2017).
In summary, we propose that GHSROS is an oncogene that regulates cancer hallmarks
and the expression of a number of genes, including the tumor suppressor PPP2R2C –
the loss of which is an emerging alternative driver of prostate cancer. Further studies are
needed to elucidate the expression and function ofGHSROS inmore detail and to determine
whether pharmacological targeting of this lncRNA could prove useful for treating cancer.
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